中国药理学通报2024，Vol.40Issue(4)：601-605,5.DOI:10.12360/CPB202206081
细胞衰老与特发性肺纤维化药物治疗研究进展
Research progress in cellular senescence and drug therapy of idiopathic pulmonary fibrosis
摘要
Abstract
Idiopathic pulmonary fibrosis(IPF)is a devastating lung disease of unknown etiology characterized by the deposition of extracellular matrix proteins,such as collagen and fibronectin,in the interstitium of the lung,leading to respiratory failure.Our understanding of the pathobiology of IPF remains incomplete;however,it is generally accepted that aging is a major risk factor for the disease.Senescence is a complex process characterized by irreversible cell cycle arrest and secretory senescence-associ-ated phenotype(SASP),leading to the continuous accumulation of senescent cells and the development of inflammation.Cellular senescence is closely related to pulmonary fibrosis disease pro-gression.This review mainly discusses the molecular mechanism of cellular senescence,telomere shortening,mitochondrial dys-function,autophagy deficiency,apoptosis resistance related to cellular cellular in the pathogenesis of IPF and the anti-aging drugs used to treat IPF,so as to provide the theoretical basis and therapeutic methods for the future treatment of IPF.关键词
特发性肺纤维化/细胞衰老/衰老相关表型/端粒缩短/线粒体功能障碍/自噬不足/细胞凋亡抵抗/治疗Key words
idiopathic pulmonary fibrosis/cellular senescence/senescence-associated secretory phenotype/telomere shortening/mitochondrial dysfunction/autophagy deficiency/apoptosis re-sistance/treatment分类
医药卫生引用本文复制引用
任正肖,张颖颖,车萍,李紫薇,朱庆均..细胞衰老与特发性肺纤维化药物治疗研究进展[J].中国药理学通报,2024,40(4):601-605,5.基金项目
山东省自然科学基金项目(No ZR2020MH384) （No ZR2020MH384）
山东省重点研发计划(重大科技创新工程)(No 2020CXGC010505) （重大科技创新工程）
